Sanacora G

Modulation of GABA and glutamate by ketamine in depression: A systematic review and meta-analysis of magnetic resonance spectroscopy studies.

Singh B, Ali HM, Miola A +8

Comment on Esketamine 5 Years After Approval: Welcome New Data With Continuing Questions.

Ahmed M, Cabrera P, Doherty T +4

Cognitive Behavioral Therapy Following Esketamine for Major Depression and Suicidal Ideation for Relapse Prevention: The CBT-ENDURE Randomized Trial.

Wilkinson ST, Kitay BM, Macaluso M +10

Long-Term Safety and Maintenance of Response With Esketamine Nasal Spray in Participants With Treatment-Resistant Depression: Interim Results of the SUSTAIN-3 Study.

Zaki N, Chen LN, Lane R +7

Non-inferiority, comparative effectiveness study of intravenous ketamine v. intranasal esketamine for treatment-resistant depression: The EQUIVALENCE trial protocol.

Wilkinson ST, Prashad S, Dalthorp R +10

Comment on Esketamine Treatment for Depression in Adults: A PRISMA Systematic Review and Meta-Analysis.

Canuso CM, Bossie C, Fu DJ +12

ArticlePsilocybin

Placebo Effects in the Treatment of Depression-Implications for the Psychedelic Renaissance.

Ansari M, Elliott SI, Holmes SE +1

Ketamine for Depression, but at What Cost? A Review of Ketamine's Neurotoxic Effects From Preclinical and Human Studies.

Li SW, Kumpf KT, Urrutia J +3

Real-World Safety of Esketamine Nasal Spray: A Comprehensive Analysis Almost 5 Years After First Approval.

Sanacora G, Ahmed M, Brown B +11

ArticlePsychedelics

Safety and Efficacy of the NMDA-2b-Selective Negative Allosteric Modulator BI 1569912: A Phase Ib Randomized Trial in Major Depressive Disorder.

McIntyre RS, Sanacora G, Walling DP +7

Genetics of Response to ECT, TMS, Ketamine and Esketamine.

Franklin CE, Altinay M, Bailey K +17

Safety and efficacy with esketamine in treatment-resistant depression: long-term extension study.

Zaki N, Chen LN, Lane R +10

Ketamine Versus Electroconvulsive Therapy for the Treatment of Depression: A Guide for Clinicians.

Elliott SI, B Katz R, B Ostroff R +3

Real-World Safety of Esketamine Nasal Spray: A Comprehensive Analysis of Esketamine and Respiratory Depression.

Chepke C, Shelton R, Sanacora G +3

Effect of Esketamine Nasal Spray on Cognition in Patients With Treatment-Resistant Depression: Results From Four Phase 3 Studies.

Morrison RL, Singh J, Daly E +8

The Role of Awe and Other Psychological Factors in Ketamine's Mechanism of Antidepressant Action.

Ansari M, Sanacora G

The Rapidly Shifting Ketamine Landscape in the US.

Wilkinson ST, Palamar JJ, Sanacora G

Ketamine and the neurobiology of depression: Toward next-generation rapid-acting antidepressant treatments.

Krystal JH, Kaye AP, Jefferson S +4

ArticlePsilocybin

Psychedelic renaissance: Revitalized potential therapies for psychiatric disorders.

Rhee TG, Davoudian PA, Sanacora G +1

Cognitive behavioral therapy following esketamine for major depression and suicidal ideation for relapse prevention: The CBT-ENDURE randomized clinical trial study protocol.

Kitay BM, Murphy E, Macaluso M +10

Treatment-resistant depression: definition, prevalence, detection, management, and investigational interventions.

McIntyre RS, Alsuwaidan M, Baune BT +24

ArticlePsychedelics

The Intricate Interaction Between Expectations and Therapeutic Outcomes of Psychedelic Agents.

Colloca L, Nikayin S, Sanacora G

ArticlePsilocybin

Single-Dose Psilocybin Treatment for Major Depressive Disorder: A Randomized Clinical Trial.

Raison CL, Sanacora G, Woolley J +31